(TNF)-related apoptosis-inducing ligand (TRAIL) is able to activate the extrinsic apoptotic
pathway upon binding to DR4/TRAIL-R1 and/or DR5/TRAIL-R2 receptors. Structural data …

Abstract Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand, also called apo-2
ligand (TRAIL/Apo-2L), is a cytokine that triggers apoptosis by binding to TRAIL-R1 (DR4) …

During the last years, a great effort has been invested into developing new TRAIL
formulations with increased bioactivity, trying to overcome the resistance to conventional …

The tumour microenvironment is very complex, and essential in tumour development and
drug resistance. The endothelium is critical in the tumour microenvironment: it provides …

Although TRAIL (TNF-related apoptosis-inducing ligand, also known as Apo2L) was
described as capable of inducing apoptosis in transformed cells while sparing normal cells …

Cancer resistance to treatments is a challenge that researchers constantly seek to
overcome. For instance, TNF-related apoptosis-inducing ligand (TRAIL) is a potential good …

Sarcomas are rare and heterogeneous cancers classically associated with a poor outcome.
Sarcomas are 1% of the cancer but recent estimations indicate that sarcomas account for …

Exosomes are cell-secreted extracellular vesicles, which contain an array of biomolecules,
such as proteins, mRNAs, microRNAs, and lipids, take part in intercellular communication …

Background/Aim: Targeting the extrinsic apoptotic pathway is an interesting option for
anticancer therapy. A protein which such ability is Apo2 ligand, also known as TNF-related …

High-risk human papillomaviruses (HPV) are the causative agents of virtually all cases of
cervical cancer and up to 80% of head and neck squamous cell carcinoma (HNSCC) …